Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-06-28
1998-12-08
Hutzel, Paula K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
4241851, 4242781, 514 2, 514 9, 514903, 530317, A61K 3800
Patent
active
058469338
ABSTRACT:
The application concerns a method of identifying compounds that can be used to inhibit undesired human CD4.sup.+ T cell immune responses by identifying compounds that block the interaction of CD4 and MHC, class II, gene products and a method of treatment which comprises administering such an identified compound. The compounds that inhibit undesired human CD4.sup.+ T cell immune responses can be used to treat disease such as multiple sclerosis and to prevent graft rejection and graft versus host disease. More specifically, the application concerns compounds having molecular weights between about 1400 and 400 that mimic three portions of the human CD4 lymphocyte cell surface antigen. The portions are residues 29-35, the C-C' loop of the D1 domain; residues 317-323, the C-C' loop of the D4 domain; and residues 346-353, the CDR3 or FG ridge of the D4 domain of the CD4 molecule. Specific examples of such compounds include cyclic peptides and peptidomimetic.
REFERENCES:
patent: 4963657 (1990-10-01), Pixley
patent: 5109123 (1992-04-01), Reinherz et al.
Satoh et al BBRC 224 pp. 438-443, 1996.
Osband et al Immunology Today 11(6) pp. 193-195, 1990.
R. Mehta et al., "Synthetic Peptides of Human CD4 Enhance Binding of Immunoglobulins to Monocyte/Macrophage Cells," Cellular Immunology, 156:146-154 (1994).
M. Goodman et al., "Tropochemical Design of Bioactive Peptides and Peptidomimetics," 18(10-11):1375-1393 (1992).
Acha-Orbea, H., et al., 1988, Cell 54:263-273.
Hafler, D.A., et al., 1988, J. Immunol. 141:131-138.
Jameson, B.A., et al., 1994, Nature 368:744-746.
Lindsey, J.W., et al., 1994, Animals of Neurology 36:183-189.
Racadot, E. et al., 1993, J. Autoimmunity 6:771-786.
Steinman, L., et al., 1981, Proc. Natl. Acad. Sci. USA 78:7111-7114.
Waldor, M.K., et al., 1985, Science 227:415-17.
Wraith, D.C., et al., 1989, Cell 59:247-255.
Zhang, X., et al., 1996, Nature Biotechnology, 14:472-475.
Huang Ziwei
Korngold Robert
Bakalyar Heather A.
Hutzel Paula K.
LandOfFree
CD-4 derived peptides that inhibit immune responses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CD-4 derived peptides that inhibit immune responses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD-4 derived peptides that inhibit immune responses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-177264